

Basic Science (October 2006)

1. Ashraf N, Zino S, MacIntyre A, Kingsmore D, Payne AP, George WD, Shiels PG. Altered sirtuin expression is associated with node-positive breast cancer. *Br J Cancer* 2006; **95**: 1056–1061.
2. Avivar A, Garcia-Macias MC, Ascaso E, Herrera G, O'Connor JE, de Mora JF. Moderate overexpression of AIB1 triggers pre-neoplastic changes in mammary epithelium. *FEBS Lett* 2006; **580**: 5222–5226.
3. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. *Clin Cancer Res* 2006; **12**: 5615–5621.
4. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. *Br J Cancer* 2006; **95**: 1220–1228.
5. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eekhout J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M. Genome-wide analysis of estrogen receptor binding sites. *Nat Genet* 2006; **38**: 1289–1297.
6. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. *Endocrinology* 2006; **147**: 4831–4842.
7. Cheng SH, Horng CF, West M, Huang E, Pittman J, Tsou MH, Dressman H, Chen CM, Tsai SY, Jian JJ, Liu MC, Nevins JR, Huang AT. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. *J Clin Oncol* 2006; **24**: 4594–4602.
8. Curran EM, Judy BM, Duru NA, Wang HQ, Vergara LA, Lubahn DB, Estes DM. Estrogenic regulation of host immunity against an estrogen receptor – negative human breast cancer. *Clin Cancer Res* 2006; **12**: 5641–5647.
9. Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, Piccart M, Larsimont D. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. *Mol Cancer Ther* 2006; **5**: 2572–2579.
10. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. *Cancer Res* 2006; **66**: 9509–9518.
11. Desmedt C, Sotiriou C. Proliferation – the most prominent predictor of clinical outcome in breast cancer. *Cell Cycle* 2006; **5**: 2198–2202.
12. Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellowell J, Wolverton D, Hwang ES, Hylton NM. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. *J Clin Oncol* 2006; **24**: 4603–4610.
13. Gaudet MM, Chanock S, Lissowska J, Berndt SI, Peplonska B, Brinton LA, Welch R, Yeager M, Mikolajczak AB, Garcia-Closas M. Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk. *Cancer Res* 2006; **66**: 9781–9785.
14. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B. TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. *Mol Cell Biol* 2006; **26**: 7632–7644.
15. Gort EH, Groot AJ, van de Ven T, van der Groep P, Verlaan I, van Laar T, van Diest PJ, van der Wall E, Shvarts A. Hypoxia-inducible factor-1 alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. *Oncogene* 2006; **25**: 6123–6127.
16. Haas S, Pierl C, Harth V, Pesch B, Rabstein S, Bruning T, Ko Y, Hamann U, Justenhoven C, Brauch H, Fischer HP. Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. *Int J Cancer* 2006; **119**: 1785–1791.

17. Hill A, McFarlane S, Mulligan K, Gillespie H, Draffin JE, Trimble A, Ouhtit A, Johnston PG, Harkin DP, McCormick D, Waugh DJJ. Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells. *Oncogene* 2006; **25**: 6079–6091.
18. Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Tobey EM, Smith SL, Isselbacher KJ, Shioda T. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. *Cancer Res* 2006; **66**: 10153–10161.
19. Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, van de Vijver MJ. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. *Clin Cancer Res* 2006; **12**: 5705–5712.
20. Li ZP, Jiao XM, Wang CG, Ju XM, Lu YN, Yuan LP, Lisanti MP, Katiyar S, Pestell RG. Cyclin D1 induction of cellular migration requires p27(KIP1). *Cancer Res* 2006; **66**: 9986–9994.
21. Liang XQ, Zhao J, Hajivandi M, Wu R, Tao J, Amshey JW, Pope RM. Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. *J Proteome Res* 2006; **5**: 2632–2641.
22. Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu XC, Kim H, Sporn MB. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor – negative model of breast cancer. *Clin Cancer Res* 2006; **12**: 5902–5909.
23. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG. The HOXB13: IL7BR expression index is a prognostic factor in early-stage breast cancer. *J Clin Oncol* 2006; **24**: 4611–4619.
24. McLachlan E, Shao Q, Wang HL, Langlois S, Laird DW. Connexins act as tumor suppressors in three-dimensional mammary cell organoids by regulating differentiation and angiogenesis. *Cancer Res* 2006; **66**: 9886–9894.
25. Milne RL, Ribas G, Gonzalez-Neira A, Fagerhohn R, Salas A, Gonzalez E, Dopazo J, Nevanlinna H, Robledo M, Benitez J. ERCC4 associated with breast cancer risk: a two-stage case-control study using high-throughput genotyping. *Cancer Res* 2006; **66**: 9420–9427.
26. Mussi P, Liao L, Park SE, Ciana P, Maggi A, Katzenellenbogen BS, Xu J, O'Malley BW. Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland. *Proc Natl Acad Sci USA* 2006; **103**: 16716–16721.
27. Myers E, Hill ADK, Kelly G, McDermott EW, O'Higgins NJ, Young LS. A positive role for PEA3 in HER2-mediated breast tumour progression. *Br J Cancer* 2006; **95**: 1404–1409.
28. Nakuci E, Mahner S, DiRenzo J, ElShamy WM. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells. *Exp Cell Res* 2006; **312**: 3120–3131.
29. Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rouge C, Ursule L, Nguyen C, Bibeau F, Rodriguez C, Theillet C. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q. *Br J Cancer* 2006; **95**: 1439–1447.
30. Padilla-Banks E, Jefferson WN, Newbold RR. Neonatal exposure to the phytoestrogen genistein alters mammary gland growth and developmental programming of hormone receptor levels. *Endocrinology* 2006; **147**: 4871–4882.
31. Riggs KA, Wickramasinghe NS, Cochrum RK, Watts MB, Klinge CM. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. *Cancer Res* 2006; **66**: 10188–10198.
32. Rodrik V, Gomes E, Hui L, Rockwell P, Foster DA. Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. *FEBS Lett* 2006; **580**: 5647–5652.
33. Roylance R, Gorman P, Papior T, Wan YL, Ives M, Watson JE, Collins C, Wortham N, Langford C, Fiegler H, Carter N, Gillett C, Sasieni P, Pinder S, Hanby A, Tomlinson I. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. *Oncogene* 2006; **25**: 6544–6553.
34. Shekhar MPV, Tait L, Gerard B. Essential role of T-cell factor/beta-catenin in regulation of Rad6B: a potential mechanism for Rad6B overexpression in breast cancer cells. *Mol Cancer Res* 2006; **4**: 729–745.
35. Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. *Cancer Res* 2006; **66**: 10120–10126.
36. Thomsen AR, Almstrup K, Nielsen JE, Sorensen IK, Petersen OW, Leffers H, Breinholt VM. Estrogenic effect of soy isoflavones on mammary gland morphogenesis and gene expression profile. *Toxicol Sci* 2006; **93**: 357–368.

37. Townson SM, Kang KY, Lee AV, Oesterreich S. Novel role of the RET finger protein in estrogen receptor-mediated transcription in MCF-7 cells. *Biochem Biophys Res Commun* 2006; **349**: 540–548.
38. Vellon L, Menendez JA, Lupu R. A bidirectional “alpha nu beta(3) integrin-ERK1/ERK2 MAPK” connection regulates the proliferation of breast cancer cells. *Mol Carcinogen* 2006; **45**: 795–804.
39. Weaver AM, Silva CM. Modulation of signal transducer and activator of transcription 5b activity in breast cancer cells by mutation of tyrosines within the transactivation domain. *Mol Endocrinol* 2006; **20**: 2392–2405.
40. Wegrán F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, Lizard-Nacol S. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. *Clin Cancer Res* 2006; **12**: 5794–5800.
41. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu YL, Curtis-Snell L, Tomes L, Watson PH, Murphy LC. Estrogen receptor-alpha phosphorylated at Ser(118) is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. *Cancer Res* 2006; **66**: 10162–10170.
42. Wilson GR, Cramer A, Welman A, Knox F, Swindell R, Kawakatsu H, Clarke RB, Dive C, Bundred NJ. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. *Br J Cancer* 2006; **95**: 1410–1414.
43. Wu GJ, Guo ZM, Chatterjee A, Huang X, Rubin E, Wu F, Mambo E, Chang X, Osada M, Kim MS, Moon C, Califano JA, Ratovitski EA, Gollin SM, Sukumar S, Sidransky D, Trink B. Overexpression of glycosylphosphatidylinositol (GPI) transamidase subunits phosphatidylinositol glycan class T and/or GPI anchor attachment 1 induces tumorigenesis and contributes to invasion in human breast cancer. *Cancer Res* 2006; **66**: 9829–9836.
44. Wu KM, Li AP, Rao M, Liu MR, Dailey V, Yang Y, Di Vizio D, Wang CG, Lisanti MP, Sauter G, Russell RG, Cvekl A, Pestell RG. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. *Mol Cell Biol* 2006; **26**: 7116–7129.
45. Wu W, Zou M, Brickley DR, Pew T, Conzen SD. Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells. *Mol Endocrinol* 2006; **20**: 2304–2314.
46. Wu XY, Chen HX, Parker B, Rubin E, Zhu T, Lee JS, Argani P, Sukumar S. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. *Cancer Res* 2006; **66**: 9527–9534.
47. Xu J, Zhou JY, Wu GS. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. *Cancer Res* 2006; **66**: 10092–10099.
48. Yu J, Henske EP. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberlin and the small GTPase ras homologue enriched in brain. *Cancer Res* 2006; **66**: 9461–9466.